Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.812,44
    +41,37 (+0,12%)
     

  • Dow Jones

    40.589,34
    +654,27 (+1,64%)
     

  • Nasdaq

    17.357,88
    +176,16 (+1,03%)
     

  • Nikkei 225

    37.667,41
    -202,10 (-0,53%)
     

  • Petrolio

    76,44
    -1,84 (-2,35%)
     

  • Bitcoin EUR

    62.931,49
    +1.086,51 (+1,76%)
     

  • CMC Crypto 200

    1.383,12
    +52,52 (+3,95%)
     

  • Oro

    2.385,70
    +32,20 (+1,37%)
     

  • EUR/USD

    1,0858
    +0,0008 (+0,08%)
     

  • S&P 500

    5.459,10
    +59,88 (+1,11%)
     

  • HANG SENG

    17.021,31
    +16,34 (+0,10%)
     

  • Euro Stoxx 50

    4.862,50
    +51,22 (+1,06%)
     

  • EUR/GBP

    0,8439
    +0,0002 (+0,02%)
     

  • EUR/CHF

    0,9590
    +0,0032 (+0,33%)
     

  • EUR/CAD

    1,5015
    +0,0027 (+0,18%)
     

Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner

Chr. Hansen Holding A/S
·1 minuto per la lettura
Chr. Hansen Holding A/S
Chr. Hansen Holding A/S

DECEMBER 12, 2022 – ANNOUNCEMENT NO. 13

Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.


Please see attachment.


CONTACT INFORMATION

Novozymes:

Investor Relations
Tobias Cornelius Björklund
+45 3077 8682
tobb@novozymes.com

Chr. Hansen:

Investor Relations
Anders Mohr Christensen
+45 2515 2364
dkamc@chr-hansen.com

 

Press Relations
Lina Danstrup
+45 3077 0552
lind@novozymes.com

Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com

Attachment